What is the imaging agent?

Fluorescing dye, which is commonly used in the procedures of oncology to highlight abnormal growth, is known as a imaging agent. Different reagent reagents are designed to target tumors based on unusual growth patterns and metabolic needs of malignant mass. Some reagents not only distinguish between healthy and cancer cells, but also between different types of cancer. Using the imaging agent, oncologists can diagnose, monitor therapeutic regimens and evaluate the range of metastases. Radiological technicians manage an agent orally, intravenously or enema. Depending on the part or structure of the body to be visualized, patients may also receive a imaging agent through an artery or in a particular cavity of the body. Substances are usually eliminated with urine or in the evacuation of fecal waste. Patients usually receive instructions on the procedure that indicate an increase in fluid intake to speed up the elimination process.

Early imaging agents not only targeted and highlighted tumors, but drove from matter after cell or death damage. The imaging agent continued the fluores and illuminated the trail to other areas. Scientists have invented various compounds that fluores only in a living cell and stop when leaving the dead or dying cells. One of these later formulations includes Boron-Dipyrromethen, often called bodypia, which only fluoresses in living cells. Scientists also modified the substance by connecting certain molecules that focused on targeting specific tumors, allowing bodypia to illuminate breast cancer with (human epidermal growth factor) HER-2 protein.

Oncologists often a imaging agent known as 18f-fluorodeoxyglucose (18F FDG) for malignant detection of matter. Tumor cells grow and reproduce at accelerated speeds compared to normal tissue, which means they havea higher level of nutrition consumption. The merged 18F FDG contains a sugar molecule that absorbs tumor cells rapidly to meet nutritional requirements. However, the fluorescent compound effectively illuminates the growth of malignant cells in bone tissue. Instead, sodium fluoride-18 (18 NAF) is used to produce lighting in bone tissue, and oncologists often combine this agent with 18F FDG to visualize the presence of tumors in soft and bone tissues.

Fluorescing compounds can also be used to monitor the growth of tumor by analyzing the development of vascular structures in malignant tissue and around. Using vascular endothelial growth factor (VEGF), a protein common to all malignant tissues, doctors monitor the development of blood vessels formed by a tumor. Might radiologists will also use certain compounds to identify cancer and determine treatment. The 18F-Fluoromisonidazole (FMISO) imaging agent detects tissues that have reduced oxygen levels. These cancer generally have a poor response to chemotherapy or radiation.